Tcheng, J E <br/><br/>
Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.  [electronic resource] 

 -  The American journal of cardiology  Aug 1996 
 - 35-40 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0002-9149 
<br/><br/><label>Standard No.: </label>10.1016/s0002-9149(96)00490-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Angioplasty, Balloon, Coronary<br/>Antibodies, Monoclonal--therapeutic use<br/>Atherectomy, Coronary<br/>Constriction, Pathologic<br/>Eptifibatide<br/>Humans<br/>Immunoglobulin Fab Fragments--therapeutic use<br/>Peptides--therapeutic use<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Randomized Controlled Trials as Topic<br/>Recurrence<br/>Stents<br/>Tirofiban<br/>Treatment Outcome<br/>Tyrosine--analogs & derivatives